Patents by Inventor Eldad Melamed

Eldad Melamed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190201452
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: March 14, 2019
    Publication date: July 4, 2019
    Inventors: Daniel OFFEN, Michal DADON-NACHUM, Tali BEN-ZUR, Eldad MELAMED, David YAFFE
  • Publication number: 20180333458
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Application
    Filed: July 27, 2018
    Publication date: November 22, 2018
    Applicants: Ramot at Tel-Aviv University Ltd., BrainStorm Cell Therapeutics Ltd.
    Inventors: Avinoam KADOURI, Avihay BAR-ILAN, Eldad MELAMED, Daniel OFFEN, Ofer SADAN, Merav BAHAT-STROMZA
  • Patent number: 10052363
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Grant
    Filed: September 11, 2016
    Date of Patent: August 21, 2018
    Assignees: Ramot at Tel-Aviv University Ltd., Brainstorm Cell Therapeutics Ltd.
    Inventors: Avinoam Kadouri, Avihay Bar-Ilan, Eldad Melamed, Daniel Offen, Ofer Sadan, Merav Bahat-Stromza
  • Publication number: 20180112185
    Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 26, 2018
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel OFFEN, Merav BAHAT-STROMZA, Eldad MELAMED
  • Patent number: 9879225
    Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: January 30, 2018
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Merav Bahat-Stromza, Eldad Melamed
  • Patent number: 9717761
    Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: August 1, 2017
    Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Sandu Pitaru, Javier Ganz, Daniel Offen, Eldad Melamed
  • Publication number: 20160375098
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Application
    Filed: September 11, 2016
    Publication date: December 29, 2016
    Applicants: Ramot at Tel-Aviv University Ltd., BrainStorm Cell Therapeutics Ltd.
    Inventors: Avinoam KADOURI, Avihay BAR-ILAN, Eldad MELAMED, Daniel OFFEN, Ofer SADAN, Merav BAHAT-STROMZA
  • Patent number: 9474787
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: October 25, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., BrainStorm Cell Therapeutics Ltd.
    Inventors: Avinoam Kadouri, Avihay Bar-Ilan, Eldad Melamed, Daniel Offen, Ofer Sadan, Merav Bahat-Stromza
  • Publication number: 20160279169
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: June 13, 2016
    Publication date: September 29, 2016
    Applicants: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Daniel OFFEN, Michal DADON-NACHUM, Tali BEN-ZUR, Eldad MELAMED, David YAFFE
  • Patent number: 9365828
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: June 14, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co., Ltd.
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Publication number: 20150086517
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Inventors: Avinoam Kadouri, Avihay Bar-Ilan, Eldad Melamed, Daniel Offen, Ofer Sadan, Merav Bahat-Stromza
  • Patent number: 8900574
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: December 2, 2014
    Assignees: Ramot at Tel-Aviv University Ltd., BrainStorm Cell Therapeutics Ltd.
    Inventors: Avinoam Kadouri, Avihay Bar-Ilan, Eldad Melamed, Daniel Offen, Ofer Sadan, Merav Bahat-Stromza
  • Publication number: 20140335059
    Abstract: The present invention provides methods and uses of neural cells differentiated from adult stem cells of the oral mucosa for cell therapy of neurological and psychiatric diseases and disorders. Methods for direction of differentiation of oral mucosal stem cells into neuronal or neuron supporting cells are also provided.
    Type: Application
    Filed: November 21, 2012
    Publication date: November 13, 2014
    Inventors: Sandu Pitaru, Javier Ganz, Daniel Offen, Eldad Melamed
  • Publication number: 20140154222
    Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel OFFEN, Merav Bahat-Stromza, Eldad Melamed
  • Publication number: 20140140968
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicants: BrainStorm Cell Therapeutics Ltd., Ramot at Tel-Aviv University Ltd.
    Inventors: Avinoam KADOURI, Avihay BAR-ILAN, Eldad MELAMED, Daniel OFFEN, Ofer SADAN, Merav BAHAT-STROMZA
  • Patent number: 8663987
    Abstract: An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: March 4, 2014
    Assignees: Ramot at Tel-Aviv University Ltd., BrainStorm Cell Therapeutics Ltd.
    Inventors: Avinoam Kadouri, Avihay Bar-Ilan, Eldad Melamed, Daniel Offen, Ofer Sadan, Merav Bahat-Stromza
  • Patent number: 8647874
    Abstract: An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: February 11, 2014
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Merav Bahat-Stromza, Eldad Melamed
  • Publication number: 20130344041
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 26, 2013
    Applicants: Yeda Research and Development Co., Ltd., Ramot at Tel-Aviv University
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe
  • Publication number: 20130236964
    Abstract: A method of treating a neurodegenerative disorder is provided. The method is effected by administering to an individual in need thereof cells capable of exogenously regulatable neurotransmitter synthesis thereby treating the neurodegenerative disorder.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 12, 2013
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventors: Eldad MELAMED, Daniel Offen, Yosef Levy, Pnina Green